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The development and assessment of treatment protocols for
children with medulloblastoma, the commonest malignant brain
tumour of childhood, has led to the understanding that not all
patients share the same disease risk. Indeed, a number of clinical
variables have been identified that enable the division of patients
into 2 broad risk groups. Patients greater than 3 years of age, with
no evidence of metastatic disease at diagnosis, who achieve total
or near-total tumour resection are regarded as ‘standard’ risk.
Around 80% of these cases may be expected to achieve cure
(Zeltzer et al, 1999; Kortmann et al, 2000). In contrast, younger
patients, or those with ≥ 1.5 cm2 of residual disease after surgery
and/or evidence of metastasis fare much worse, demonstrating
long-term survival rates of equal to or less than 50% (Zeltzer et al,
1999; Kortmann et al, 2000). 
The capacity to stratify patients with medulloblastoma on the
basis of disease risk has undoubted clinical value, enabling the
tailoring of treatment intensity to the level of disease aggression.
Unfortunately, although clinical variables permit broad distinc-
tions to be made between patient risk groups, when used alone
they have proved an unreliable basis for assigning therapy. For
example, a recent joint Children’s Cancer Group (CCG) and
Pediatric Oncology Group (POG) study (CCG-923/POG-8631)
which randomised ‘standard’ risk medulloblastoma patients to
receive reduced (23.4 Gy) versus standard (36 Gy) neuraxis radio-
therapy, was closed early after an increased risk of relapse was
detected among patients in the reduced treatment arm (Thomas 
et al, 2000). Furthermore, although a second, non-randomised
CCG study (CCG-9892) of 23.4 Gy neuraxis radiotherapy in
patients with non-metastatic medulloblastoma aged greater than 
3 years achieved a 3-year progression-free survival rate in excess
of 90%, the study’s authors raised appropriate concern regarding
the observed pattern of disease relapse (Packer et al, 1999). Of 
14 cases experiencing treatment failure, 12 patients suffered
disease recurrence outside the primary site. 
Together, these data suggest that while the concept of ‘standard’
risk medulloblastoma is likely to be real, clinical variables alone
are an insufficient means of accurately defining disease risk.
Stratification on the basis of both clinical and molecular prog-
nostic markers, potentially provides a more accurate means of
identifying patients for trials of treatment reduction. Therefore, in
the current study we have investigated the prognostic significance
of 3 molecular markers (ErbB2 oncogene protein expression,
abnormality of chromosome 17 and MYC oncogene amplifica-
tion), previously implicated in promoting aggressive biological
behaviour in medulloblastoma (Badiali et al, 1991; Cogen, 1991;
Batra et al, 1995; Gilbertson et al, 1997a, 1997b; Herms et al,
1997; Scheurlen et al, 1998; Herms et al, 2000). In particular, we
have assessed the capacity of these molecular variables to provide
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rary clinical staging. 
MATERIAL AND METHODS 
Patients 
The study population included 41, consecutively treated patients,
aged ≥ 3 years, with newly diagnosed medulloblastoma, treated at
Newcastle and Southampton General Hospitals, England, between
1984 and 1997. The clinical details of each patient are summarised
in Table 1. 12 of the 41 cases were drawn from a cohort of 70
patients whose tumours were previously investigated by us for
ErbB2 expression using immunohistochemical (IHC) analysis
(Gilbertson et al, 1997a). These patients were included because
they fulfilled the eligibility criteria for the study and had not 
previously been investigated for chromosome 17 abnormality or
MYC oncogene amplification. The histological diagnosis of
medulloblastoma was confirmed according to WHO criteria
(Giangaspero et al, 2000). 19 cases fulfilled the diagnostic criteria
for desmoplastic medulloblastoma. No cases of atypical teratoid
rhabdoid tumour were identified within the study population.
Metastatic disease stage and extent of surgical resection were
assessed using a combination of pre- and postoperative CT and
MRI brain and spinal imaging. CSF sampling for the assessment
of M1 status is not routinely conducted in the United Kingdom,
therefore patients were classified as either <M2 or ≥ M2. 21
patients received standard radiotherapy (55 Gy to the primary
tumour and 35 Gy to the neuraxis) alone following surgery. In
addition to standard radiotherapy, a further 19 patients all received
and completed pre-irradiation chemotherapy randomised by the
2nd or 3rd International Society of Pediatric Oncology (SIOP)
trials (Bailey et al, 1995). The median follow up time for the 22
patients alive at last follow up was 4.5 years (range 0.2–12 years). 
Immunohistochemical (IHC) analysis of ErbB2 receptor
expression 
Protocols for the fixation and histological processing of tumour
samples were identical between the 2 study centres. Analysis of
ErbB2 expression was conducted in 5 µ m formalin-fixed paraffin
wax-embedded tumour sections using the anti-ErbB2 monoclonal
antibody NCL-CB11 (Novocastra, UK) as described in detail else-
where (Gilbertson et al, 1997a). In our previous studies a score of
greater than 50% ErbB2 immunopositive tumour cells was associ-
ated with a worse clinical outcome (Gilbertson et al, 1997a).
Therefore, in the current study, tumours were scored as either
‘high’ ErbB2 expressing (≥ 50% immunopositive tumour cells) or
‘low’ ErbB2 expressing (<50% immunopositive tumour cells) by 2
independent observers (RG and RH). No discrepancies in staining
score were encountered. 
Fluorescence in situ hybridisation (FISH) 
Fluorescence in situ hybridisation (FISH) was employed to iden-
tify both abnormalities of chromosome 17 and MYC oncogene
amplification in material derived from each of the tumour blocks
employed in the analysis of ErbB2 receptor expression. The
method is described in detail elsewhere (Nicholson et al, 2000).
For the analysis of imbalance on the short and long arms of
chromosome 17, cytospin preparations of nuclei from sections of
formalin-fixed, wax-embedded tumour or tonsillar tissue (normal
controls) were probed with a digoxigenin-labelled cosmid probe 
to the subtelomeric region of 17p (2111b1) or 17q (B37c1) in
combination with a 17 centromeric biotin-labelled plasmid probe
(D17Z1). A digoxigenin-labelled BAC probe (968N11) encom-
passing the MYC gene was combined with a biotin-labelled
plasmid probe (D8Z1) to the alpha-satellite repeat region of 
chromosome 8 for analysis of MYC amplification. FISH signals
for each case were assessed in 200 non-overlapping nuclei as
described previously (Nicholson et al, 2000). 
Statistical analysis 
Relationships between molecular and clinical markers were
assessed using Fisher’s and Chi-square exact tests. Survival was
measured from the date of initial diagnosis of medulloblastoma to
the date of death or last contact. Survival distributions were
assessed using Kaplan–Meier curves and their standard errors
calculated using the method described by Peto et al (1977). The
relatively small number of study patients, further reduced within
levels of each prognostic factor, required calculating and reporting
exact P values. The exact P value allows analysis of small, sparse
or unbalanced data because it is not based on large sample assump-
tions (Mantel, 1966). Exact tests were accomplished using the
software package StatXact (Cytel Software Corp, Cambridge,
MA). 
RESULTS 
ErbB2 receptor expression 
Sufficient tumour material was available for the analysis of ErbB2
receptor expression in all but one (case 5) of the 41 patients. 28%
(n = 9/32) of positive cases were designated as ‘high’ expressing
tumours, demonstrating intense mixed cytoplasmic and membrane
ErbB2 immunoreactivity in ≥ 50% of tumour cells (Table 1 and
Figure 1). 
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Figure 1 Immunohistochemical analysis of ErbB2 receptor expression in
medulloblastoma. Photomicrograph of a sample taken from the study
population demonstrating receptor expression in >50% of tumour cells
(mag × 200) 
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amplification 
FISH analysis of chromosome 17 was conducted in all 
41 study patients (Table 1). Loss of 17p was detected in 20 (49%)
tumours. In 12 of these, additional gain of 17q was also observed,
generating a pattern of imbalance compatible with an isochromo-
some of 17q (i(17q), Figure 2A). Loss of 17p with a normal 
17q (termed hereafter ‘isolated 17p loss’), was observed 
in the remaining 8 cases (Figure 2B). No abnormality of chromo-
some 17p could be detected in 21 (51%) study cases 
(Figure 2C). 
Availability of tumour material restricted FISH analysis of MYC
oncogene copy number to 34 cases (Table 1). Gene amplification
was observed in only 6% (n = 2/34, cases 7 and 31, Figure 2D).
Both cases demonstrated numerous copies of the MYC gene
(Figure 2D). 
Relationship between molecular, histopathological and
clinical variables 
A significant, positive relationship was observed between ‘high’
expression of the ErbB2 receptor and ‘isolated 17p loss’, with
‘normal’ or ‘i(17q)’ compatible FISH patterns occurring more
frequently in tumours with ‘low’ ErbB2 expression (P = 0.01). In
addition, a positive trend was observed between the presence of
metastases at diagnosis and ‘high’ ErbB2 tumour expression,
however this did not reach significance (P = 0.08). No other signif-
icant relationship was observed between any of the other clinico-
pathological variables. Importantly, we observed no significant
relationship between patient age and any molecular abnormality.
Specifically, no significant clustering either including or excluding
chromosome 17 abnormality, high ErbB2 expression or MYC
amplification, was seen among the 6 patients in the study popula-
tion (36–41) aged between 20 and 30 years. 
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Table 1 Summary of the clinical and molecular characteristics of the study population 
Study no. Sex Age (y) Phenotype Metastasis Surgery Therapy Follow up (months) Status Chr. 17 ErbB2 MYC
1 F 18 C Y P R 18 DOD i17q L – 
2 M 4.4 C N T CR 144 A n L – 
3 M 12 C N T CR 140 A n L – 
4 F 5 C Y P R 6 DOD –17p H – 
5 F 5 D N T R 137 A n ND – 
6 M 9.3 D Y P CR 10 DOD –17p H – 
7 M 12.7 D N T CR 109 A n L + 
8 M 19.6 D N P R 54 DOD n L – 
9 F 18.5 C N P CR 53 DOD –17p H ND 
10 M 14.3 C N P CR 121 A i17q L –  
11 M 8.5 C N P CR 40 DOD i17q L –  
12 M 6.3 C Y T CR 17 DOD i17q H –  
13 F 3.6 D N T R 104 A n L – 
14 M 9.8 C Y P CR 20 DOD i17q L – 
15 M 5.1 D N P CR 96 A i17q L – 
16 M 6.5 C N P CR 61 DOD n L ND 
17 M 3.3 C N T R 90 A i17q L ND 
18 M 5.2 D N P N 1 DOD i17q H – 
19 M 4.7 C N T CR 45 A i17q L – 
20 F 19.8 C N P R 73 A n L – 
21 M 20 C Y P R 20 DOD n L – 
22 F 4.75 C Y T CR 13 DOD –17p L – 
23 F 10 C N T CR 23 DOD –17p L – 
24 M 7.25 D N T R 57 A n L – 
25 M 6.6 C N T CR 45 A n L – 
26 M 7.5 D N T R 50 A n L – 
27 M 6.5 D N T CR 7 A n L – 
28 M 4.3 C Y T R 6 A n H – 
29 F 16.7 D N T R 11 A n L ND 
30 M 5.3 D Y P CR 42 A –17p H ND 
31 F 4.2 C N P CR 5 A n H + 
32 M 11.2 D N P R 47 A i17q L – 
33 M 6.7 C N P R 2 A n L – 
34 F 5.9 D N P CR 48 A i17q L ND 
35 M 4 D N P R 40 A n L ND 
36 M 24.7 C Y P R 18 DOD i17q L –  
37 M 30.2 D N P R 29 DOD –17p H – 
38 M 30.2 C N P R 40 DOD –17p L – 
39 M 25.6 D ND T R 77 DOD n L – 
40 F 22.7 D N T R 111 A n L – 
41 M 27.9 D Y P R 67 DOD n L – 
C, classic medulloblastoma; D, desmoplastic medulloblastoma; Y, M2+ disease; N, <M2 disease; P, partial resection; T, total resection; CR, chemotherapy and
radiotherapy; R, radiotherapy only; DOD, dead of disease; A, alive; n, ‘normal’; i17q, ‘isochromosome 17q’; –17p, ‘isolated 17p loss’ compatible FISH pattern; L,
‘Low’ (<50% ErbB2 positive tumour cells); H, ‘High; (≥ 50% ErbB2 positive tumour cells); ND, not done; –, not amplified; +, amplified. 
BJOC 01-1987 705-712  20/8/01  3:49 pm  Page 707In contrast to the report of Scheurlen and colleagues (Scheurlen
et al, 1998), we did observe 17p deletion within desmoplastic
tumours (Table 1). The low frequency of MYC oncogene amplifi-
cation observed in the current study precluded any analysis of its
relationship to other clinicopathological variables including
survival. 
Univariate survival analysis 
Among the clinical variables analysed, only the degree of tumour
resection (P = 0.007) and metastatic disease stage at diagnosis (P =
0.0006) related significantly to overall survival, confirming their
well established prognostic significance in medulloblastoma
(Zeltzer et al, 1999). In contrast, neither the type of adjuvant
therapy received (‘chemotherapy and radiotherapy’ vs. ‘radio-
therapy alone’, P = 0.8), histological subtype (P = 0.06) or age at
diagnosis (≥ 3–<10 years vs. ≥ 10 years, P = 0.07), appeared to
influence clinical outcome. However, the numbers involved in the
current study are too small to dismiss these variables as insignifi-
cant prognostic markets. The absence of a significant relationship
between patient age and survival is compatible with inclusion in
the study of only patients aged ≥ 3 years and a lack of any observed
relationship between patient age and other clinical or molecular
risk factors. 
Expression of the ErbB2 receptor and chromosome 17 subtype
were both significantly related to survival (Figures 3A, B). Of 9
patients identified with ‘high’ ErbB2 expressing tumours, 7 (78%)
have died from their disease, all within 5 years of diagnosis. This
is in contrast to only 12 deaths among 31 patients (39%) with
‘low’ expressing tumours (Figure 3A, P = 0.003). It is important to
note that only 3 of the 12 patients previously analysed by us for
ErbB2 expression had ‘high’ expressing tumours, and their inclu-
sion did not bias the statistical analysis. A significant survival
difference was also detected between at least 2 of the 3 chromo-
some 17 subgroups (Figure 3B, P = 0.013). Disease outcome was
noted to be especially poor in those patients with ‘isolated 17p
loss’. Of the 8 patients within this group, 7 (88%) have died from
their disease, 5 within 3 years of diagnosis (Figure 3B). Pairwise
analysis of patients with ‘isolated 17p loss’ and ‘normal’ chromo-
some 17 FISH pattern disease, confirmed a significant difference
in survival between these 2 groups (P = 0.003). It was not possible
to determine whether the survival of patients whose tumours were
classified as ‘i(17q)’ was significantly different from the other 2
subgroups. Indeed, while the short-term disease course of these
patients was similar to that of ‘isolated 17p loss’ cases (Figure
3B), long-term clinical outcome was closer to that of patients
whose tumours demonstrated a ‘normal’ chromosome 17 FISH
pattern, with 50% (n = 6/12) of ‘i(17q)’ cases remaining alive at
time of analysis with a median follow 69 months (range 45–121
708 R Gilbertson et al 
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Figure 2 Fluorescence in situ hybridization (FISH) analysis of medulloblastoma samples taken from patients in the study population. (A) ‘i(17q)’ compatible
pattern, showing three 17q subtelomeric (green) and two 17 centromeric (red) probe signals. (B) ‘Isolated 17p loss’ compatible pattern, showing a single 17p
subtelomeric (green) and two 17 centromeric (red) probe signals. (C) ‘Normal’ chromosome 17 compatible pattern showing two 17p subtelomeric (green) and
two 17 centromeric (red) probe signals. (D) FISH analysis of case 7 demonstrating multiple MYC oncogene probe signals (green) compatible with gene
amplification 
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17p loss’ and ‘high’ ErbB2 receptor expression are biological
markers of poor clinical outcome in patients with medullo-
blastoma. 
Close inspection of the patient population revealed 2 cases each
with ‘normal’ (cases 28 and 31) or ‘i(17q)’ (cases 12 and 18) FISH
patterns but ‘high’ expression of ErbB2, and 3 cases with ‘isolated
17p loss’,  ‘low’ ErbB2 expressing tumours (cases 22, 23, 38).
Therefore, analysis of a single molecular marker may result in
erroneous underestimation of disease risk for patients whose
tumour harbours only one abnormality. To study this further,
patients were divided into 2 molecular risk groups. ‘High’ molec-
ular risk patients were designated as those with ‘high’ ErbB2
receptor expression and/or ‘isolated 17p loss’, while ‘low’ molec-
ular risk patients were designated as patients whose tumours
demonstrated neither aberration. Of 12 patients classed as molec-
ular ‘high’ risk, 83% (n = 10/12) have died from their disease, 8
within 3 years of diagnosis. In contrast, only 32% (n = 9/28) of
‘low’ molecular risk patients have succumbed to their disease.
This risk stratification enabled a greater level of resolution
between patients with ‘high’ and ‘low’ risk disease than any 
clinical or molecular marker analysed individually (Figure 4A, 
P = 0.0001). 
Survival analysis following clinical risk stratification 
The principal aim of this study was to establish whether molecular
abnormalities provide prognostic information for patients with
medulloblastoma additional to that afforded by clinical risk strati-
fication. Therefore, we repeated the survival analysis of molecular
risk groups, but first stratified patients for either metastatic disease
stage or the degree of surgical resection. 
Molecular disease risk stratification in medulloblastoma 709
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Figure 3 Kaplan–Meier survival curves demonstrating the influence of
molecular prognostic markers on the overall survival rate of patients 
in the study population. (A) ErbB2 receptor expression and survival. 
(B) Chromosome 17 aberration detected by FISH and survival 
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Figure 4 Kaplan–Meier survival curves demonstrating the prognostic
significance of molecular risk group alone (A), and in combination with
clinical factors (B) metastatic stage (< M2 vs. ≥ M2 disease) and (C) extent
of surgical resection (‘total’ vs. ‘partial’) 
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metastatic, high molecular risk’ ( n = 6), ‘non-metastatic, low
molecular risk’ (n = 22), ‘metastatic, high molecular risk’ (n = 6)
or ‘metastatic, low molecular risk’ (n = 5). Patients with ‘non-
metastatic, low molecular risk’ disease (n = 22) had a significantly
better survival than any other risk group, with only 3 of these cases
(13%) dying from disease and median follow-up time in the 20
surviving cases exceeding 5 years (Figure 4B, P = 0.0005). Of
particular note, 5 of 6 patients presenting with ‘non-metastatic,
high molecular risk’ tumours, died from their disease within 5
years of diagnosis, indicating the ability of molecular risk stratifi-
cation to refine disease risk attributed by clinical variables alone. 
The value of combining clinical and molecular risk staging was
illustrated further following stratification according to degree of
surgical resection (Figure 4C). Patients were again grouped into 1
of 4 categories: ‘partial resection, high molecular risk’ (n = 8),
‘partial resection, low molecular risk’ (n = 15), ‘total resection,
high molecular risk’ (n = 4) or ‘total resection, low molecular risk’
(n = 14). Of the 14 patients undergoing total resection of low mole-
cular risk tumours, only 1 patient (7%) has died from disease.
Furthermore, the median survival time of the remaining 13 cases
has exceeded 7 years (median 90 months, range 11–144), with no
evidence of disease relapse at time of follow up (Figure 4C).
Although patient numbers in these risk groups are small, exact log-
rank analysis again allowed a cohort of particularly good-risk
patients to be clearly resolved from the remaining 3 categories,
including those patients with ‘totally resected, high molecular
risk’ tumours (Figure 4C, P = 0.0001), indicating the additional
prognostic information afforded by molecular risk stratification. 
DISCUSSION 
The treatment of medulloblastoma is at an impasse. Around 80%
of patients currently classified by clinical criteria as ‘standard’ risk
may achieve long-term survival (Zeltzer et al, 1999). However, the
majority will suffer major neurological and endocrine side effects
secondary to neuraxis radiotherapy (Schwartz, 1999). Attempts to
reduce the intensity of radiation treatment in these patients have
proved difficult due to unacceptable relapse rates (Packer et al,
1999; Thomas et al, 2000). Furthermore, treatment options for
patients with macroscopic metastases at diagnosis or for those
whose disease fails to respond to conventional therapy are
extremely limited, with 40% and under 5% of such cases respec-
tively achieving cure (Zeltzer et al, 1999; Kortmann et al, 2000). 
These observations provide 2 clear challenges for the future
management of children with medulloblastoma. First, additional
markers other than clinical factors are required if we are to identify
those patients who can be cured with reduced therapy. Second, it is
imperative that novel therapeutic approaches are developed to
improve the survival of patients with more aggressive disease. It is
likely that these challenges will be met only by improved knowl-
edge of the biology of medulloblastoma. To this end, we investi-
gated the frequency and prognostic significance of ErbB2 receptor
expression, chromosome 17 abnormalities and MYC amplification
in the largest combined analysis of these molecular abnormalities
in medulloblastoma to be conducted to date. For the first time, 
we provide evidence that molecular factors may allow increased
accuracy over clinical stratification alone in the assignment of
medulloblastoma disease risk. 
In the current study, amplification of the MYC oncogene was
identified in only 6% of analysed tumours (n = 2/34, cases 9 and
34). This incidence is identical to the overall MYC amplification
rate of 6% (n = 9/132 total tumours analysed) reported by the
majority of published studies (Badiali et al, 1991; Batra et al,
1995; Herms et al, 2000). One group has identified MYC
amplification in 17% (5/29) of medulloblastomas. However, this
increased frequency is likely to reflect the nature of their study
material which included primary tumours from clinically high-risk
patients, including patients less than 3 years of age and samples of
CSF metastases (Scheurlen et al, 1998). Most published studies
have reported an adverse effect of MYC amplification on clinical
outcome (Badiali et al, 1991; Batra et al, 1995). Although the
small number of MYC-amplified cases detected in the current
series precluded formal survival analysis, it is noteworthy that one
patient (7) remains alive and disease-free more than 9 years after
diagnosis. 
Deletions involving the short arm of chromosome 17 represent
the most frequent genetic abnormality in medulloblastoma, occur-
ring in 40–50% of primary tumours (Cogen, 1991; Batra et al,
1995; Emadian et al, 1996; Biegel et al, 1997; Scheurlen et al,
1997, 1998; Nicholson et al, 2000). Susceptibility to 17p deletion
appears to result from the presence of at least 4 breakpoint cluster
regions distributed within the centromeric, Charcot–Marie–Tooth
and Smith–Magenis syndrome loci of 17p (Scheurlen et al, 1997),
and may occur in the absence of other gross abnormalities of 17, or
more frequently as a component of an i(17q) (Scheurlen et al,
1997; Nicholson et al, 2000). In keeping with these studies, we
identified loss of the telomeric region of 17p in 49% (n = 20/41) 
of tumours, with 60% (n = 12/20) of these cases demonstrating
concurrent gain of 17q compatible with the formation of an i(17q). 
At present, the clinical and molecular significance of 17p dele-
tion in medulloblastoma remains unclear. Although a number of
studies in the literature have reported a significantly worse prog-
nosis for patients whose tumours harbour deletions of 17p (Cogen,
1991; Batra et al, 1995; Scheurlen et al, 1997) this has not been 
a universal finding (Emadian et al, 1996; Biegel et al, 1997).
However, these studies have involved only small numbers of cases
or employed a variety of techniques with different sensitivities to
analyse 17p loss, thereby rendering them difficult to interpret.
Very recently, data was presented suggesting that the hypermethy-
lated in cancer-l gene (HIC-1) located at 17p 13.3 may represent
an important gene deleted by such abnormalities, thereby acting as
a potential tumour suppressor for medulloblastoma (Eberhart et al,
1999). In the current study, we employed a single, sensitive tech-
nique to detect aberration of chromosome 17 in a relatively large,
well characterised series of patients and identified a significantly
worse clinical outcome for cases whose tumours had ‘isolated 
17p loss’ compared to a ‘normal’ chromosome 17 FISH pattern
(Figure 3B). Patient numbers were too small in our analysis to
allow statistical resolution of the survival of patients with an
‘i(17q)’ compatible pattern from those with ‘isolated 17p loss’.
However, the current study does provide preliminary evidence that
these 2 may represent clinically and biologically distinct tumour
subtypes. First, compared to the catastrophic disease course
observed among ‘isolated 17p loss’ cases, the 5-year survival rate
of patients whose tumours displayed an ‘i(17q)’ compatible FISH
pattern was 50%, with a median disease-free follow-up time in
surviving patients of 69 months (range 45–121 months) (Figure
3B). Second, in our analysis of the relationship between ErbB2
expression and chromosome 17 abnormality, while the majority 
of chromosome 17 ‘normal’ (n = 18/21) and i(17q) (n = 10/12)
compatible tumours demonstrated ‘low’ receptor levels, 5 of 8
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sion (P = 0.01). Further analysis is required to establish whether
ErbB2 overexpression and ‘isolated 17p loss’ are functionally
related or represent independent markers of aggressive disease. 
The ErbB2 receptor plays a central role in the signalling
network formed by the 4 members of the ErbB tyrosine kinase
receptor family and their cognate ligands (Olayioye et al, 2000).
Operating as the preferred dimer partner of the 3 other family
members, this receptor mediates the transduction of potent, highly
transforming cellular signals (Olayioye et al, 2000). Considerable
evidence exists in the literature implicating the ErbB2 receptor in
the pathogenesis of human cancer including medulloblastoma
(Gilbertson et al, 1997a, 1997b; Herms et al, 1997; Olayioye et al,
2000). We initially reported a significant relationship between
elevated tumour cell proliferation (Gilbertson et al, 1997b) and
reduced long-term survival (Gilbertson et al, 1997a) in patients
with medulloblastoma who expressed the ErbB2 receptor in 
≥ 50% of tumour cells. These data are supported by the results of
the current study in which 5-year overall survival rates of 66 ±
11% and 0% were observed for patients with ‘low’ and ‘high’
ErbB2 expressing tumours, respectively (Figure 3A, P = 0.003). 
The principal aim of the current study was to investigate the
hypothesis that the combined assessment of clinical and molecular
prognostic markers may allow increased accuracy of disease-risk
stratification for patients with medulloblastoma. Data from the
current study strongly support this hypothesis. First, although the
‘extent of surgical resection’, ‘metastatic stage’, ‘level of ErbB2
expression’ and ‘isolated 17p loss’ were all powerful prognostic
indicators, no significant relationship could be identified between
clinical and molecular factors. This suggests that patients identi-
fied as ‘high’ or ‘low’ risk disease by clinical stratification do not
completely overlap with those stratified by molecular subgroup
analyses. Second, the requirement for multiple rather than single
molecular factor analysis was supported by the observation in 7
(17%) tumours of either ‘high’ expression of ErbB2 or ‘isolated
17p loss’ but not both molecular aberrations. Finally, combined
clinical and molecular factor analysis enabled the resolution of a
subset of patients with a particularly favourable disease outcome
(Figure 4B, C). For example, only 3 of 22 patients with non-
metastatic  ‘low’ molecular risk disease have died from their
disease with a median survival of 65 months in surviving patients
(range 2–144 months). This is in contrast to 5 deaths among 6
cases with non-metastatic, ‘high’ molecular risk disease, the 1
surviving patient having follow up of only 5 months. Similar
results were also achieved in the analysis of surgical resection and
disease risk (Figure 4C). Of particular note, all patients in the
study (n = 12) undergoing total resection of non-metastatic, ‘low
molecular risk’ tumours are alive and disease free with a median
follow up of 73 months. Only one other case (23) in the study
population achieved total resection of a non-metastatic tumour.
This patient had ‘high molecular risk’ disease and died within 2
years of diagnosis. 
We are currently seeking to confirm these results in a larger
prospective study of patients with medulloblastoma. It is hoped
that combined analysis of clinical and molecular risk stratification
may significantly improve disease management efficiency, and in
particular allow more accurate identification of patients who may
be cured with reduced therapy. In this regard it will also be impor-
tant in future studies to analyse the interaction between molecular
genetic abnormalities and treatment response. Neuraxis radiation
therapy is routinely employed in medulloblastoma because of the
high propensity of this tumour to disseminate throughout the CNS.
Although only a non-significant trend between high ErbB2 expres-
sion and stage ≥ M2 was observed in the current study, we have
previously reported a significant relationship between the presence
of metastatic disease at diagnosis and high ErbB2 immunoreac-
tivity (Gilbertson et al, 1998). Therefore, tumours expressing low
levels of this receptor may indeed exhibit a lower metastatic poten-
tial and represent a subgroup in which reduced dose neuraxis
radiotherapy may be rationally applied. 
Finally, molecular aberrations important in maintaining an
aggressive tumour phenotype may also represent potential targets
for novel therapeutic approaches. In this regard, the ErbB2
receptor has received considerable attention following the
successful development and use of the anti-ErbB2 therapeutic
monoclonal antibody Herceptin, in the management of women
with high ErbB2-expressing metastatic breast cancer (Cobleigh 
et al, 1999). Recently we demonstrated that the ErbB2 receptor can
be targeted to achieve growth inhibitory effects against medul-
loblastoma cells in vitro (Gilbertson et al, 1999). Further studies
are underway to investigate whether this may indeed represent a
potential new therapeutic approach for childhood medullo-
blastoma. 
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